BioCentury
ARTICLE | Clinical News

Cotsiranib: Ph IIa started

February 16, 2017 8:14 PM UTC

Sirnaomics began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 20, 30 and 40 μg/cm2/day intradermal cotsiranib twice weekly for 4 weeks in about 24 patients. Patients will recei...

BCIQ Company Profiles

Sirnaomics Ltd.

BCIQ Target Profiles

Cyclooxygenase-2 (COX-2) mRNA